Generic Altabax Availability

Altabax is a brand name of retapamulin topical, approved by the FDA in the following formulation(s):

ALTABAX (retapamulin - ointment;topical)

  • Manufacturer: GLAXO GRP LTD
    Approval date: April 12, 2007
    Strength(s): 1% [RLD]

Has a generic version of Altabax been approved?

No. There is currently no therapeutically equivalent version of Altabax available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altabax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Process salts compositions and use
    Patent 7,875,630
    Issued: January 25, 2011
    Inventor(s): Breen; Gary Francis & Forth; Michael Anthony & Kopelman; Susan ShuMei Hu & Muller; Francis Xavier & Sanderson; Francis Dominic
    Assignee(s): Glaxo Group Limited
    The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.
    Patent expiration dates:
    • February 14, 2027
      ✓ 
      Drug substance
  • Pleuromutilin derivatives as antimicrobials
    Patent RE39128
    Issued: June 13, 2006
    Inventor(s): Berry; Valerie Joan & Dabbs; Steven & Frydrych; Colin Henry & Hunt; Eric & Sanderson; Francis Dominic & Woodnutt; Gary
    Assignee(s): SmithKline Beecham p.l.c.
    The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
    Patent expiration dates:
    • April 12, 2021
      ✓ 
      Patent use: TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pleuromutilin derivatives as antimicrobials
    Patent RE43390
    Issued: May 15, 2012
    Inventor(s): Berry; Valerie Joan & Dabbs; Steven & Frydrych; Colin Henry & Hunt; Eric & Sanderson; Francis Dominic & Woodnutt; Gary
    Assignee(s): GlaxoSmithKline LLC SmithKline Beecham Limited
    The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
    Patent expiration dates:
    • April 12, 2021
      ✓ 
      Patent use: TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)